Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (SUPN) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring President and CEO Jack Khattar and Senior VP and CFO Tim Dec.
The presentation will include Q1 2025 financial and business results, followed by a Q&A session. Investors can access the live webcast through the Events & Presentations section of Supernus' Investor Relations website. Pre-registration is available for participants, who will receive a personalized conference code. A replay will be available on the company's website for 60 days following the live call.
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in upcoming March investor conferences. Jack Khattar, President and CEO, will represent the company at these events.
The company will feature a fireside chat at the Barclays Global Healthcare Conference, which will be available via live audio webcast. Investors can access the webcast through the Events & Presentations section of Supernus's website at www.supernus.com. The webcast recording will remain accessible for 60 days following the conference.
Interested investors seeking meetings with Supernus management during these conferences should reach out to the respective conference coordinators for arrangements.
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
President and CEO Jack A. Khattar will engage in a fireside chat on March 3, 2025, at 11:10 a.m. ET in Boston, Mass. Interested investors can arrange meetings with management through the conference coordinator.
The presentation will be accessible via live audio webcast through the company's website investor relations section, with a replay available for 60 days post-conference.
Supernus Pharmaceuticals (SUPN) reported strong financial results for Q4 and full year 2024, with total revenues increasing 9% to $661.8 million. Qelbree showed exceptional growth with Q4 net sales up 60% to $74.4 million and full-year sales up 72% to $241.3 million. GOCOVRI sales also improved, rising 15% in Q4 to $36.9 million.
The company achieved full-year 2024 operating earnings of $81.7 million, compared to a loss in 2023. Notable developments include FDA approval of ONAPGO for Parkinson's disease, planned for launch in Q2 2025, and a patent extension for Qelbree until 2035.
For 2025, Supernus projects total revenues between $600-630 million and adjusted operating earnings of $105-130 million. The company maintains a strong financial position with $453.6 million in cash and marketable securities as of December 31, 2024.
Supernus Pharmaceuticals (SUPN) announced that its Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD) failed to meet its primary endpoint. The study did not show statistically significant improvement in depressive symptoms compared to placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
The trial results showed minimal difference between SPN-820 (LS mean ± Standard Error: -12.3 ± 0.96) and placebo (-11.9 ± 0.96), with no statistical significance. Secondary endpoints also showed no treatment difference. However, the drug demonstrated a favorable safety profile with few adverse events, consistent with previous clinical trials.
Supernus Pharmaceuticals (SUPN) has announced it will release its fourth quarter and full year 2024 financial results after market close on Tuesday, February 25, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec, who will present the results and host a Q&A session.
Investors can access the live webcast through the Events & Presentations section of Supernus's Investor Relations website. Pre-registration is available for participants who wish to join via phone. A replay of the call will be available on the company's website for 60 days following the live presentation.
Supernus Pharmaceuticals (SUPN) has received FDA approval for ONAPGO (apomorphine hydrochloride), the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease. The device will be available in the U.S. in Q2 2025.
The approval is based on a Phase 3, 12-week study (N=107) that demonstrated significant reduction in daily OFF time and increase in GOOD ON time. ONAPGO provides continuous treatment during waking hours through a wearable subcutaneous infusion device, offering more consistent control without requiring invasive surgery.
The treatment has a 30-year history in Europe, where it has helped thousands of patients. Supernus will launch ONAPGO with comprehensive support, including a nurse education program and access support.
Supernus Pharmaceuticals (SUPN) announced FDA approval for an updated label of its ADHD treatment Qelbree. The update includes new pharmacodynamic data detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting the drug's multimodal pharmacodynamics.
The label update also includes new lactation data showing low transfer of Qelbree into breastmilk, making it the first ADHD treatment to meet post-marketing requirements following the 2019 FDA guidance on Clinical Lactation Studies. The study, involving 15 healthy lactating women, demonstrated that the relative infant dose was approximately 1% of the maternal daily dose.
Qelbree is approved for ADHD treatment in patients 6 years and older. The medication carries important safety information, including risks of increased suicidal thoughts and actions, blood pressure elevation, and heart rate changes.
Supernus Pharmaceuticals (Nasdaq: SUPN), a CNS-focused biopharmaceutical company, announced its participation in the 36th Annual Piper Sandler Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace.
The presentation will be accessible via live audio webcast through the company's website investor relations section, with a replay available for 60 days post-conference. Investors seeking meetings with management should contact the conference coordinator.
Supernus Pharmaceuticals (Nasdaq: SUPN) has announced its participation in the 2024 Jefferies London Healthcare Conference. President and CEO Jack Khattar will engage in a fireside chat on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London.
The event will be accessible via live audio webcast through the company's website investor relations section. Interested investors can arrange meetings with management through the Jefferies conference coordinator. A replay of the webcast will remain available for 60 days following the conference on the company's website.